Clonidine
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Using the drug-repurposing evaluation report template to produce the requested report from the Clonidine evidence pack.
Note on scope: the pack contains 10 ranked candidates. Rank 1 by raw TxGNN score (“faciodigitogenital syndrome”) has zero supporting evidence (L5/Hold), while rank 5 (“Tourette syndrome”) is the only candidate reaching L1 evidence with a “Proceed with Guardrails” call, guideline backing, and RCTs — so that’s the candidate the report is built around.
Clonidine: From Hypertension to Tourette Syndrome
One-Sentence Summary
Clonidine is a central α2-adrenergic receptor agonist whose established clinical use — reflected throughout the collected literature (essential/resistant hypertension studies) — is as an antihypertensive agent that reduces central sympathetic outflow. The TxGNN model predicts it may be effective for Tourette Syndrome, with 3 clinical trials and 19 publications currently supporting this direction, including a European clinical guideline and two recent randomized controlled trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available as a discrete registration field; drug is classified as an α2-adrenergic agonist and the collected evidence repeatedly references its established antihypertensive use |
| Predicted New Indication | Tourette Syndrome |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L1 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the structured drug record (flagged as a High-severity data gap — DG002). Based on information present in the evidence pack itself, clonidine acts as a central α2-adrenergic receptor agonist that reduces noradrenergic outflow from the locus coeruleus, an action that underlies both its blood-pressure-lowering effect and its established use as a tic-suppressing agent.
Tourette syndrome is a neurodevelopmental disorder driven in part by dysregulated noradrenergic/dopaminergic tone in the basal ganglia and locus coeruleus. Reducing central noradrenergic drive is a plausible mechanistic bridge between clonidine’s original pharmacology and tic suppression — and this is not merely theoretical: clonidine has been used off-label for tic disorders since the late 1970s and is already named as a first-line option in the 2022 European clinical guidelines for Tourette syndrome (PMID 34757514).
A 2025 preclinical study (PMID 40392363) further proposes an anti-inflammatory mechanism — clonidine reducing IL-2-driven neuroinflammation in the basal ganglia in a rat model of Tourette syndrome — adding a second, independent mechanistic hypothesis alongside the classic noradrenergic-suppression rationale.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00370838 | Phase 4 | Completed | 12 | Head-to-head comparison of levetiracetam vs. clonidine for tic suppression in children with Tourette syndrome |
| NCT00152750 | Phase 4 | Unknown | 32 | Tested whether clonidine-treated sleep improvement reduces daytime aggression in children with TS + comorbid ADHD |
| NCT01172288 | Phase 2 | Completed | 31 | N-acetylcysteine vs. placebo trial in pediatric TS; clonidine mentioned only as a comparator standard-of-care agent, not the study drug |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39258554 | 2024 | RCT | Clinical Neuropharmacology | Randomized, double-blind, placebo-controlled multicenter trial of clonidine adhesive patch in Tourette syndrome |
| 38695046 | 2024 | RCT | Psychiatry Investigation | Efficacy/safety of clonidine patch in TS patients with comorbid ADHD |
| 34757514 | 2022 | Guideline | Eur Child Adolesc Psychiatry | European clinical guidelines for TS and tic disorders — pharmacological treatment section |
| 36528030 | 2023 | Review (network meta-analysis) | Lancet Child & Adolescent Health | Comparative efficacy/tolerability of pharmacological interventions for TS across age groups |
| 31061209 | 2019 | Review (systematic) | Neurology | Systematic review of efficacy and risks of tic treatments |
| 34286606 | 2021 | Review (systematic) | J Psychopharmacology | Quality-of-evidence review of pharmacological treatments for TS |
| 89558 | 1979 | Clinical study | Lancet | Foundational report: low-dose clonidine improves TS in children unresponsive to haloperidol |
| 1414629 | 1992 | Cohort/Clinical study | Advances in Neurology | Clinical experience with clonidine and clonazepam in Tourette syndrome |
| 24210663 | 2014 | Clinical study | Psychiatry Research | Clonidine’s effect on sensorimotor gating in Tourette syndrome |
| 40392363 | 2025 | Preclinical (rat model) | J Neuroimmune Pharmacology | Proposes clonidine ameliorates neuroinflammation as a novel TS mechanism |
India Market Information
Currently no India market registration is on file (market status: Not Marketed; 0 registrations recorded).
Safety Considerations
- Drug Interactions: 234 total interactions on file (DDInter, all listed as Moderate severity). Notable clusters include corticosteroids (hydrocortisone, dexamethasone, betamethasone, budesonide, triamcinolone), antidiabetic agents (SGLT2 inhibitors — canagliflozin, dapagliflozin, empagliflozin, ertugliflozin; sulfonylureas — glimepiride, glipizide, glyburide, chlorpropamide, acetohexamide; insulins), and CNS-active agents (morphine, bupropion, dronabinol) — relevant to glycemic control and additive CNS/cardiovascular depression risk.
Package insert warnings and contraindications are flagged as a data gap (DG001, Blocking severity) and are not yet available for review.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Tourette syndrome is the only candidate in this evidence pack reaching L1 evidence strength, supported by a current European clinical guideline, two 2024 RCTs of a clonidine patch formulation, and continuous clinical use dating back to 1979 — but the drug has no existing India market registration and its formal label safety data is missing.
To proceed, the following is needed:
- Resolve DG001 (Blocking): obtain and parse the official product label for warnings/contraindications before any S1 safety screening can proceed
- Resolve DG002 (High): confirm detailed MOA documentation from DrugBank to firm up the mechanistic linkage
- A route-to-market assessment, since clonidine currently has zero registrations locally
- A dosing/formulation decision (patch vs. oral) informed by the 2024 RCTs, given no local product exists yet
- Review of the 234-item DDI list against likely comorbid TS medications (stimulants, antipsychotics) before clinical guardrails are finalized
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.